Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|March 1, 2004

BioPharm International

  • BioPharm International-03-01-2004
  • Volume 17
  • Issue 3

Site Expansion - Regional Roundup: Delaware

Regional Roundup: Delaware

Population (2002)
805,945
Workforce population (2002)
423,200
Unemployment rate (10/02)
4.3%
Key cities and populations
Wilmington: 72,485; Newark: 29,652; Dover: 32,299
Targeted industries
Biotech, agriculture, information technology, tourism, banking and finance, transportation, venture capital
Biopharm employment (2002)
15,224
Academia and government affiliated with biopharm industry
Delaware Technology Park; Delaware Biotech Institute; University of Delaware
Primary business strengths
Extensive pool of scientists and engineers; similar industries based in Delaware; broad regional network of specialized suppliers; one of the lowest costs of doing business regionally
Tax and other incentives
Competitive tax structure, including no state or local general sales tax; no personal property or inventory taxes; real property taxes are among the lowest in the US; corporate income tax credits and reduction of gross receipts taxes for new and expanded businesses; additional tax credits on corporate income and reduction of gross receipt taxes for new and expanding businesses locating in 30 targeted census tracts; property tax relief for new construction and improvements of existing property; the exemption of certain investment and holding companies from corporate income tax; the adherence of the state tax structure to the federal definition of corporate net income so companies may take full advantage of any federal tax law change, such as more rapid depreciation of newly purchased assets. Also, two approved foreign trade zones will allow the deferment of import taxes; Public Utility Tax rebates of 50% on increased consumption for qualifying industries, and reduced rate for manufacturers and agricultural processors. (Visit
BioClusters
Delaware Technology Park:
State committment to biopharm industry growth
Legislative funding; restructuring of Delaware Economic Development Office to clusters one cluster is devoted to life sciences and biotechnology; the state plans to continue to attract new biopharm companies
State- and regional-level contacts
Delaware Economic Development Office, 302.577.8477, Bob Dayton

Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.